HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Monograph User Fees Up To $34M Floated In Senate Discussion Draft

This article was originally published in The Rose Sheet

Executive Summary

Bulk of user fees would be raised through facility fees, under Sens. Isakson and Casey’s discussion draft, but there's little time to add the changes to FDA user fee reauthorization bills already moving in Congress.

You may also be interested in...



Trump's Budget Surprise: FDA Gets 13% Increase

President Trump's FY 2019 budget request includes $473m in new non-user fee revenue for the US agency, a reversal of the previous year's request.

OTC Monograph Reform Momentum Carries Potential Exclusivity Snag

Support was unanimous during House Health Subcommittee markup for draft legislation on streamlining FDA's monograph system by eliminating public rulemakings from the process and allowing the agency to make decisions with administrative orders. Two-year exclusivity for some products didn't go over so well.

Rep. Pallone Galvanized By FDA's 'Troubling Overview' Of Cosmetic Imports

FDA physically inspected less than 1% of the 2.9m cosmetic imports that reached the US in fiscal 2016, according to a letter from the agency released by Congressman Frank Pallone. The ranking member of the House Energy and Commerce Committee says he's aiming for a hearing in September on his bipartisan proposal to increase FDA's authority over the cosmetics sector.

Related Content

Topics

UsernamePublicRestriction

Register

RS109265

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel